Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

2,395 questions in 172 reviews · Gut

current versions

No studies 420 · 17.5%Ungraded 60 · 2.5%Very low 821 · 34.3%Low 602 · 25.1%Moderate 397 · 16.6%High 95 · 4%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Sulphasalazine vs placebo Health related quality of life (HRQL) · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
5‐ASA vs no treatment Serious adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
5‐ASA vs no treatment Withdrawal due to adverse events · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 5 [0.25, 101.81]	1 study · 110 participants	Very low
5‐ASA vs no treatment Health related quality of life · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
5‐ASAs vs placebo Clinical relapse · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.83 [0.72, 0.96]	5 studies · 730 participants	Moderate
5‐ASAs vs placebo Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.83 [0.56, 1.24]	3 studies · 537 participants	Very low
Homeopathy vs placebo Global improvement (Asafoetida subgroup) · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	RR 1.61 [1.18, 2.18]	2 studies · 129 participants	Very low
Homeopathy vs usual care Abdominal pain · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs usual care Stool frequency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs usual care Stool consistency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs usual care Adverse events · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs usual care Global improvement (IBS‐SSS) · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	1 study · 76 participants	Low
Homeopathy plus usual care vs usual care Quality of life · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	1 study · 76 participants	Low
Homeopathy plus usual care vs usual care Abdominal pain · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs usual care Stool frequency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs usual care Stool consistency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs usual care Adverse events · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Global improvement (Asafoetida + nux vom subgroup) · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	RR 1.31 [0.8, 2.15]	1 study · 42 participants	Very low
Homeopathy plus usual care vs supportive listening plus usual care Global improvement (IBS‐SSS) · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	1 study · 34 participants	Very low
Homeopathy plus usual care vs supportive listening plus usual care Quality of life · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	1 study · 34 participants	Very low
Homeopathy plus usual care vs supportive listening plus usual care Quality of life · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs supportive listening plus usual care Abdominal pain · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs supportive listening plus usual care Stool frequency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs supportive listening plus usual care Stool consistency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy plus usual care vs supportive listening plus usual care Adverse events · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Quality of life · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Abdominal pain · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Stool frequency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Stool consistency · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs placebo Adverse events · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Homeopathy vs usual care Global improvement (Feeling unwell) · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	1 study · 20 participants	Very low
Homeopathy vs usual care Quality of life · patients with irritable bowel syndrome Homeopathy for treatment of irritable bowel syndrome (2019) · Cochrane	no estimate extracted	NR	No studies
Azathioprine or 6‐mercaptopurine vs placebo Clinical relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.79 [0.67, 0.92]	3 studies · 408 participants	Moderate
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid Radiologic relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.92 [0.66, 1.28]	1 study · 35 participants	Very low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid Surgical relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.81 [0.5, 1.29]	1 study · 142 participants	Very low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid Adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.89 [0.74, 1.07]	4 studies · 346 participants	Low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid Serious adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 3.39 [1.26, 9.13]	3 studies · 311 participants	Very low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid Withdrawal due to adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 2.21 [1.28, 3.81]	4 studies · 425 participants	Low
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Clinical relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 2.89 [1.5, 5.57]	3 studies · 139 participants	Very low
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Endoscopic relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 3.67 [1.05, 12.81]	4 studies · 157 participants	Very low
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Radiologic relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	2 studies · 117 participants	Ungraded
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Surgical relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 1.13 [0.83, 1.53]	2 studies · 117 participants	Low
Azathioprine or 6‐mercaptopurine vs placebo Endoscopic relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.85 [0.64, 1.13]	2 studies · 321 participants	Low
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Serious adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 0.51 [0.17, 1.54]	1 study · 84 participants	Very low
Azathioprine or 6‐mercaptopurine vs anti TNF‐α Withdrawal due to adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 3.97 [0.92, 17.22]	3 studies · 139 participants	Low
Azathioprine or 6‐mercaptopurine vs placebo Radiologic relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
Azathioprine or 6‐mercaptopurine vs placebo Surgical relapse · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	no estimate extracted	NR	No studies
Azathioprine or 6‐mercaptopurine vs placebo Adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 1.36 [0.57, 3.27]	2 studies · 168 participants	Low
Azathioprine or 6‐mercaptopurine vs placebo Serious adverse events · People with surgically‐induced remission in Crohn's disease Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease (2019) · Cochrane	RR 1.78 [0.39, 8.18]	2 studies · 327 participants	Low